Vla-4 inhibitors

Abstract

The present invention relates to a compound represented by the following formula (I): (wherein, W represents W-A-W- (in which, Wis substituted or unsubstituted aryl, etc., Ais —NR—, single bond, —C(O)—, etc., and Wis substituted or unsubstituted arylene, etc.), R is single bond, —NH—, —OCH—, alkenylene, etc., X is —C(O)—, —CH—, etc., and M is, for example, the following formula: (in which, R, Rand Reach independently represents hydrogen, hydroxyl, amino, halogen, etc., Ris hydrogen or lower alkyl, Y represents —CH—O—, etc., Z is substituted or unsubstituted arylene, etc., Ais single bond, etc, and Ris hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VLA-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.